Search - tctmd.com

Displaying 1 - 20 of 26

Sort: Relevancy | Date

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

News Conference News CX Symposium 2025

Bioresorbable Scaffold for CLTI Appears to Be an Economical Option: LIFE-BTK

April 24, 2025

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

News Conference News ESC 2024

New ESC Guidelines Merge PAD, Aortic Diseases Into Single Document

September 10, 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

January 24, 2024

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

October 25, 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

News Conference News LINC 2023

PROSPECT MONSTER: Real-World Data Confirm Low-Dose DCB Efficacy in PAD

June 21, 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

News Conference News LINC 2023

What Works, What’s Noise? Novel Approaches Offer Hope in CLTI

June 07, 2023

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

November 03, 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

April 04, 2022

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

October 08, 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

October 07, 2021

As Paclitaxelgate Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

November 27, 2020

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

November 13, 2019

EffPac: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

May 23, 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

January 30, 2019

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

News Conference News ISET 2018

WISE LE Data Build the Case for Embolic Protection in Lower-Extremity Atherectomy

February 13, 2018

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

News Conference News VIVA 2017

DCBs, Stents, and ‘Swirling Flow’ Show Promise in Femoropopliteal Disease

September 13, 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

News Conference News ISET 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

February 07, 2017

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

September 20, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.